Literature DB >> 10698878

HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests.

J H Tosswill1, G P Taylor, R S Tedder, P P Mortimer.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10698878      PMCID： PMC27302          DOI： 10.1136/bmj.320.7235.611

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Population review: (8). The ethnic minority and overseas-born populations of Great Britain.

Authors:  J Haskey
Journal:  Popul Trends       Date:  1997

2.  Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis.

Authors:  E Tynell; S Andersson; E Lithander; M Arneborn; J Blomberg; H B Hansson; A Krook; M Nomberg; K Ramstedt; A Shanwell; A Bjorkman
Journal:  BMJ       Date:  1998-05-09

3.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

4.  Surveillance of HTLV infection in England and Wales: 1986-1992.

Authors:  I Simms; J H Tosswill; A Noone; D Morgan
Journal:  Commun Dis Rep CDR Rev       Date:  1994-05-27
  4 in total
  14 in total

1.  HTLV-1 is lower in blood donors in West Midlands than South Thames.

Authors:  J Kurtz; N Smith; S Harbour
Journal:  BMJ       Date:  2000-08-05

2.  Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study.

Authors:  A E Ades; S Parker; J Walker; M Edginton; G P Taylor; J N Weber
Journal:  BMJ       Date:  2000-06-03

Review 3.  Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

Authors:  Unsong Oh; Steven Jacobson
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

4.  In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.

Authors:  Silva Hilburn; Aileen Rowan; Maria-Antonietta Demontis; Aidan MacNamara; Becca Asquith; Charles R M Bangham; Graham P Taylor
Journal:  J Infect Dis       Date:  2011-01-05       Impact factor: 5.226

5.  Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Yoshihisa Yamano; Tomoo Sato
Journal:  Front Microbiol       Date:  2012-11-09       Impact factor: 5.640

6.  Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Authors:  Graham P Taylor; Peter Goon; Yoshitaka Furukawa; Hannah Green; Anna Barfield; Angelina Mosley; Hirohisa Nose; Abdel Babiker; Peter Rudge; Koichiro Usuku; Mitsuhiro Osame; Charles R M Bangham; Jonathan N Weber
Journal:  Retrovirology       Date:  2006-09-19       Impact factor: 4.602

7.  HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.

Authors:  Heather A Niederer; Daniel J Laydon; Anat Melamed; Marjet Elemans; Becca Asquith; Masao Matsuoka; Charles R M Bangham
Journal:  Virol J       Date:  2014-09-30       Impact factor: 4.099

8.  Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses.

Authors:  Georgina Ireland; Sara Croxford; Jennifer Tosswill; Rajani Raghu; Katy Davison; Patricia Hewitt; Ruth Simmons; Graham Taylor
Journal:  Euro Surveill       Date:  2017-05-18

9.  Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report.

Authors:  Veronica Lyell; Elham Khatamzas; Theresa Allain
Journal:  J Med Case Rep       Date:  2007-07-25

10.  Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

Authors:  Ariella L G Coler-Reilly; Naoko Yagishita; Hiroko Suzuki; Tomoo Sato; Natsumi Araya; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2016-05-25       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.